Detalhe da pesquisa
1.
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
N Engl J Med
; 386(7): 655-666, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172056
2.
Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.
J Infect Dis
; 225(12): 2087-2096, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216113
3.
A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
Antimicrob Agents Chemother
; 64(2)2020 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31712214
4.
Barriers to healthcare-worker adherence to infection prevention and control practices in British Columbia during the coronavirus disease 2019 (COVID-19) pandemic: A cross-sectional study.
Infect Control Hosp Epidemiol
; 45(4): 474-482, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37941386
5.
Barriers to infection prevention and control in long-term care/assisted living settings in British Columbia during the COVID-19 pandemic: a cross-sectional survey.
Antimicrob Resist Infect Control
; 12(1): 84, 2023 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37649046
6.
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
Antimicrob Agents Chemother
; 54(10): 4451-63, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20660667
7.
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
PLoS One
; 13(12): e0204099, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586365
8.
A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model.
PLoS One
; 11(12): e0166113, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27936016
9.
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Antivir Chem Chemother
; 27: 2040206619895706, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31856576
10.
Challenging the assertion of comparability of surveillance and administrative data.
Infect Control Hosp Epidemiol
; 39(11): 1391-1392, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30284523
11.
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
J Acquir Immune Defic Syndr
; 62(2): 171-9, 2013 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23328090
12.
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
J Virol
; 81(5): 2359-71, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17182681
13.
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Antimicrob Agents Chemother
; 49(11): 4721-32, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16251317